Martínez ÁJC

Language: Spanish
References: 23
Page: 81-88
PDF size: 147.45 Kb.

ABSTRACT

With the onset of the AIDS epidemic, major changes occurred in blood banking and transfusion medicine. These changes occurred mainly in donor selection and screening tests for infectious diseases, blood centers modified their organizational philosophy regarding quality. Transfusion of blood products are procedures that allow us to correct the haematology deficiencies for which was indicated. But today, despite the strict controls that precede transfusion, recipients may have undesirable effects, which are known as adverse effects or adverse reactions to transfusion. Antibodies and antigens of the HLA system plays a role in a series of events related to transfusion, such as immunological platelet refractoriness, febrile non-haemolytic transfusion reactions, transfusion related acute lung injury (TRALI) and transfusion-associated graft-versus-host disease. The determination of anti-HLA antibodies is evidence that in most developed countries is used on a daily basis in the regular assessment of patients multitransfused or waiting lists for organs from deceased donors. The biomodulators are able to modify biological responses which act in sequence to lead to the differentiation of T lymphocytes. These agents may subcategorizes those which facilitate a normal immune response, those stimulates the immune response, those are capable of inducing immunosuppression not cytotoxic, and those enhancing the ability of the host to tolerate damage by cytotoxic treatment (transfusion or transplant).

REFERENCES

1. McCullough J. The role of physicians in blood centers. Transfusion. 2006;46:854-9.

2. Asociación Americana de Bancos de Sangre. Manual técnico. 13.a Ed. AABB, Maryland USA. 2001. p. 593.

3. Ralf K, Rodeina D, Paul A, et al. Guidelines for use of RFID technology in transfusion medicine. Vox Sang. 2010;98:1-24.

4. Resink H, Panzer S, Gonzalez C, et al. Haemovigilance for the optimal use of blood products in the hospital. Vox Sang. 2010;99:278-93.

5. World Health Organization. Blood transfusion safety, Handbook The Clinical use of Blood. Geneva, Switzerland. Ed. WHO 2001.

6. Charron D. HLA, immunogenetics, pharmacogenetics and personalized medicine. Vox Sang. 2011;100:163-6.

7. Martínez AJC. Importancia del CMH en el trasplante de células progenitoras hematopoyéticas de cordón umbilical y seguimiento del injerto. Gac Méd Méx. 2004;140 Suppl 3:64-7.

8. Gilson CR. MHC II on transfused murine blood is not required for alloimmunization against MHCI. Vox Sang. 2010;99:369-74.

9. Brown CJ. Clinical relevance of the HLA system in blood transfusion. Vox Sang. 2011;101:93-105.

10. Kiefel V, Köning C, Kroll H, et al. Platelet alloantibodies in transfused patients. Transfusion. 2001;41:766-70.

11. Sanz C, Freire C, Alcorta I, et al. Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion. 2001;41:762-5.

12. Brand A. Alloimmune platelet refractoriness: incidence declines, unsolved problems persist. Transfusion. 2001;41:724-6.

13. Brubaker DB. Clinical significance of white cell antibodies in febrile nonhemolytic transfusion reactions. Transfusion. 1990;30:733-7.

14. Tazzari PL, Bontadini A, Zamagni C, et al. Febrile non-hemolytic transfusion reaction caused by antibodies against human platelet antigen 5a. Transfus Med. 2005;15:443-4.

15. Fedeyi EA, Adams S, Sheldon S, et al. A preliminary comparison of the prevalence of transfusion reactions in recipients of platelet components from donors with and without human leukocyte antigen antibodies. Vox Sang. 2008;94:324-8.

16. Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol. 2007;14:682-7.

17. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion related acute lung injury: statement of a consensus panel. Transfusion. 2004;44:1774-89.

18. Davis A, Mandal R, Johnson M, et al. A touch of TRALI. Transfusion. 2008;48:541-5.

19. Agbaht K, Altintas ND, Topeli A, et al. Transfusion-associated graftversus- host disease in immunocompetent patients: case series and review of the literature. Transfusion. 2007;47:1405-11.

20. Wisecarver JL, Cattral MS, Langnas A, et al. Transfusion-induced graftversus- host disease after liver transplantation. Transplantation. 1994;58:269-71.

21. Blajchman MA, Dzik S, Vamvakas EC, et al. Clinical and molecular basis of transfusion-induced immunomodulation: summary of the proceedings of a state-of-the art conference. Transfus Med Rev. 2001;15: 108-35.

22. Opelz G, Sengar DP, Mickey MR. Effect of blood transfusions on subsequent kidney transplants. Transpl Proc. 1973;5:253-9.

23. Gharesi-Fard B, Zolghadri J, Foroughinia L, et al. Effectiveness of leukocyte immunotherapy in primary recurrent spontaneous abortion (RSA). Iran J Immunol. 2007;4:173-8.